Primary treatment for melanoma remains surgical excision with negative margins. Unfortunately, melanoma margins cannot be visualized or palpated;as a result surgeons obtain wide margins of healthy appearing tissue based on tumor histology and depth of penetration. Failure to improve surgical cures contributes to a failure to improve survival in this disease while most other cancer types have shown dramatically improved survival over the same time period. Improving melanoma survival depends on improving the primary treatment modality. We propose to determine if FDA approved antibodies to commonly expressed melanoma antigens can be leveraged for imaging of microscopic margins and regional disease. We propose to identify the optimal antibody (or combinations) for imaging, the sensitivity and specificity of this technique and the mechanisms by which it promotes fluorescence in the tumor. Using this strategy, histological margins can be selectively obtained and normal tissues spared. If successful such a technique would dramatically impact how surgical resections are performed.

Public Health Relevance

Although primary treatment for melanoma remains surgical excision with negative margins, tumor margins are very difficult to determine on inspection or on frozen section. We propose to determine if FDA approved antibodies to commonly expressed melanoma antigens can be leveraged for intraoperative imaging of primary tumors, microscopic margins and regional disease. If successful such a technique would dramatically change how oncological surgery is performed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA179171-02
Application #
8699170
Study Section
Clinical Molecular Imaging and Probe Development (CMIP)
Program Officer
Zhang, Yantian
Project Start
2013-07-10
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Surgery
Type
Schools of Medicine
DUNS #
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Sweeny, Larissa; Prince, Andrew; Patel, Neel et al. (2016) Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies. Laryngoscope 126:E387-E395
Warram, Jason M; de Boer, Esther; Korb, Melissa et al. (2015) Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW. Br J Neurosurg 29:850-8
Warram, Jason M; de Boer, Esther; Moore, Lindsay S et al. (2015) A ratiometric threshold for determining presence of cancer during fluorescence-guided surgery. J Surg Oncol 112:2-8
Chung, Thomas K; Warram, Jason; Day, Kristine E et al. (2015) Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol Ther 16:790-8
Zinn, Kurt R; Korb, Melissa; Samuel, Sharon et al. (2015) IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. Mol Imaging Biol 17:49-57
Rosenthal, Eben L; Warram, Jason M; Bland, Kirby I et al. (2015) The status of contemporary image-guided modalities in oncologic surgery. Ann Surg 261:46-55
Rosenthal, Eben L; Warram, Jason M; de Boer, Esther et al. (2015) Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clin Cancer Res 21:3658-66
Warram, Jason M; de Boer, Esther; Sorace, Anna G et al. (2014) Antibody-based imaging strategies for cancer. Cancer Metastasis Rev 33:809-22
Day, Kristine E; Sweeny, Larissa; Kulbersh, Brian et al. (2013) Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol 15:722-9
Day, Kristine E; Beck, Lauren N; Deep, Nicholas L et al. (2013) Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma. Laryngoscope 123:2681-9

Showing the most recent 10 out of 11 publications